ID   TLBR-2
AC   CVCL_A1EY
SY   TLBR 2; TLBR2; T-cell Lymphoma BReast-2
DR   cancercelllines; CVCL_A1EY
DR   Cosmic; 2814461
DR   DSMZ; ACC-905
DR   DSMZCellDive; ACC-905
DR   GEO; GSM2527950
DR   Wikidata; Q102114991
RX   PubMed=22791880;
RX   PubMed=28356514;
CC   Doubling time: 37 hours (PubMed=22791880); ~24-30 hours (DSMZ=ACC-905).
CC   Sequence variation: Mutation; HGNC; HGNC:11364; STAT3; Simple; p.Asp661Tyr (c.1981G>T); ClinVar=VCV000928790; Zygosity=Unspecified (PubMed=28356514).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): DSMZ=ACC-905
ST   Amelogenin: X
ST   CSF1PO: 11,12,13
ST   D13S317: 8
ST   D16S539: 12
ST   D18S51: 15,16
ST   D19S433: 12,13
ST   D21S11: 31,32.2
ST   D2S1338: 16,24
ST   D3S1358: 14,17
ST   D5S818: 11,13
ST   D7S820: 11,12
ST   D8S1179: 12,16
ST   FGA: 21
ST   Penta D: 10,11
ST   Penta E: 11
ST   TH01: 6
ST   TPOX: 9,11
ST   vWA: 14,16
DI   NCIt; C37194; Anaplastic large cell lymphoma, ALK-negative
DI   ORDO; Orphanet_300903; ALK-negative anaplastic large cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 19-12-24; Version: 10
//
RX   PubMed=22791880; DOI=10.1158/1078-0432.CCR-12-0101;
RA   Lechner M.G., Megiel C., Church C.H., Angell T.E., Russell S.M.,
RA   Sevell R.B., Jang J.K., Brody G.S., Epstein A.L.;
RT   "Survival signals and targets for therapy in breast implant-associated
RT   ALK -- anaplastic large cell lymphoma.";
RL   Clin. Cancer Res. 18:4549-4559(2012).
//
RX   PubMed=28356514; DOI=10.1073/pnas.1700682114; PMCID=PMC5393253;
RA   Chen J., Zhang Y., Petrus M.N., Xiao W.-M., Nicolae A., Raffeld M.,
RA   Pittaluga S., Bamford R.N., Nakagawa M., Ouyang S.T.-Y., Epstein A.L.,
RA   Kadin M.E., Del Mistro A., Woessner R.D., Jaffe E.S., Waldmann T.A.;
RT   "Cytokine receptor signaling is required for the survival of ALK-
RT   anaplastic large cell lymphoma, even in the presence of JAK1/STAT3
RT   mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:3975-3980(2017).
//